NAGE Q4 2020 Earnings — Niagen Bioscience Inc Revenue & Financial Results | Market Cap Arena

NAGENiagen Bioscience Inc

$423M

Q4 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$15M+18.0% YoY

Gross Profit

$9M61.0% margin

Operating Income

-$6M-39.4% margin

Net Income

-$6M-39.5% margin

EPS (Diluted)

$-0.10

QoQ Revenue Growth

+8.9%

Cash Flow

Operating Cash Flow

$22,000

Free Cash Flow

$45,000

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$38M

Total Liabilities

$22M

Stockholders' Equity

$16M

Cash & Equivalents

$16M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$15M	$13M	+18.0%
Gross Profit	$9M	$7M	+26.2%
Operating Income	-$6M	-$9M	+31.4%
Net Income	-$6M	-$9M	+31.1%